Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹2,065 Cr
verified against source
Revenue YoY
13%
reported change
EBITDA
₹513 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Sharda Cropchem delivered a stellar Q4 FY26, with revenue growing 13% YoY to ₹2,065 crore, EBITDA surging 75% to ₹513 crore (margin 24.8%, up 750bps), and PAT rising 57% to ₹319 crore. The full year saw revenue of ₹5,268 crore (+22% YoY) and PAT of ₹681 crore (+124% YoY). Growth was driven by volume expansion (+4.3% in Q4, +13.4% full year) and favorable forex (+11.7% in Q4), partially offset by negative price/mix (-3.0%). Gross margins expanded 750bps to 37.3% due to better product mix and pricing discipline. Management guided FY27 revenue growth of 10-15%, gross margins around 35%, and EBITDA margins of 18-20%. Key risks include geopolitical uncertainty from the Middle East war and potential raw material price increases, though management believes 80-90% of cost increases can be passed on due to limited competition from registration barriers.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects revenue to grow by 10-15% in FY27, driven by volume growth of around 15% and stable pricing.
- Gross margins are expected to stay around 35% plus or minus a few percentage points, similar to FY26 levels.
- EBITDA margins are guided to be in the range of 18-20% for FY27, down from 24.8% in Q4 but consistent with full-year FY26 levels.
- The effective tax rate is expected to be between 18-20% for FY27, similar to recent trends.
Risks flagged
- The ongoing war in the Middle East creates uncertainty in supply chains and raw material availability, though no major impact seen yet.
- Potential spike in Chinese agrochemical prices could pressure margins, though management believes 80-90% can be passed on.
- Unrealized forex losses of ₹26 crore in Q4 highlight exposure to currency fluctuations, especially USD/EUR.
- Bureaucratic delays in product registrations could slow revenue contribution from new molecules, though management downplays impact.
Key quotes
- FY 2025-26 has been by every measure the best year in Sharda Cropchem's history as a listed company.
- Normally we are able to pass because the competition is limited. We are not dealing with products which are freely tradable and registration process is very expensive and time consuming.
- We are having not more than 5% of that market share globally... we have a lot of scope to improve market share if it goes from 5% to 6% it's almost 20% increase in Sharda's business.
Research modules